Stable lipid-comprising drug delivery complexes and methods for their production
Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The biological activity of the complexes produced are comparable to the formulations prepared according to the prior art admixture method and upon purification, the complexes produced by the method of this invention are 50 to 500 fold more concentrated than the complexes formed by admixture. The method described herein provides for the large scale production of lipid-comprising drug delivery systems useful for gene therapy and other applications.
1. A noncovalent nucleic acid/lipid/polycation complex comprising a nucleic acid, at least one cationic lipid species, and a polycation, wherein the polycation is at least one protamine sulfate or chloride salt, a histone, a peptide comprising polylysine, or a peptide comprising a nuclear localization sequence of SV40 large T antigen, and wherein the noncovalent complex is formed by adding a nucleic acid to a solution comprising the cationic lipid species and the polycation.
2. The complex of claim 1 , wherein the complex has an average diameter of less than about 400 nm.
3. The complex of claim 1 , wherein the at least one protamine sulfate or chloride salt is a sulfate salt.
4. The complex of claim 1 , wherein the at least one lipid is 3β[N-(N′,N′-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol).
5. The complex of claim 1 , wherein the at least one protamine sulfate or chloride salt is from about 20 to about 100 amino acids in length.
6. The complex of claim 1 , wherein the complex further comprises a neutral phospholipid species.
7. The complex of claim 1 , wherein the ratio of the nucleic acid:lipid:polycation is about 1 μg/0.1 nmol/0.01 μg to about 1 μg/200 nmol/100 μg.
8. The complex of claim 1 , wherein the nucleic acid is DNA, RNA or an oligonucleotide.
9. The complex of claim 1 , wherein the nucleic acid is DNA or RNA.
10. The complex of claim 1 , wherein the nucleic acid is RNA.
11. A method for producing a noncovalent nucleic acid/lipid/polycation complex comprising a nucleic acid, at least one cationic lipid species, and a polycation, wherein the polycation is at least one protamine sulfate or chloride salt, a histone, a peptide comprising polylysine, or a peptide comprising a nuclear localization sequence of SV40 large T antigen.
the method comprising adding a nucleic acid to a solution comprising the cationic lipid species and the polycation to form the complex.
12. The method of claim 11 , wherein the ratio of the nucleic acid:lipid:polycation, is about 1 μg/0.1 nmol/0.01 μg to about 1 μg/200 nmol/100 μg.
13. The method of claim 11 , wherein the complex has an average diameter of less than about 400 nm.
14. The method of claim 11 , wherein the complex has a diameter of less than about 200 nm.
15. The method of claim 11 , wherein the average diameter of the complex is less than about 200 nm.
16. The method of claim 11 , wherein the diameter of the stored complex does not increase by more than 100% over the diameter of the complex as determined at the time the complex was purified, after 4 months in storage.
17. The method of claim 11 , wherein the nucleic acid is DNA, RNA or an oligonucleotide.
18. The method of claim 11 , wherein the nucleic acid is DNA or RNA.
19. The method of claim 11 , wherein the nucleic acid is RNA.
20. A method for delivering nucleic acid to cells comprising contacting the cells with the complex of claim 1 .
21. The method of claim 20 , wherein the cells are contacted with the complex in vivo, the method comprising administering the complex to an individual in an amount effective to deliver the nucleic acid into the cells of the individual.
22. The method of claim 20 , wherein the complex has an average diameter of less than about 400 nm.
23. The method of claim 20 , wherein the complex has a diameter of less than about 200 nm.
24. The method of claim 20 , wherein the average diameter of the complex is less than about 200 nm.
25. The method of claim 20 , wherein the nucleic acid is DNA, RNA or an oligonucleotide.
26. The method of claim 20 , wherein the nucleic acid is DNA or RNA.
27. The method of claim 20 , wherein the nucleic acid is RNA.
28. The method of claim 20 , wherein the complex is administered intratumorally, intravenously, intratracheally, intraperitoneally or intramuscularly.
29. The method of claim 20 , wherein the complex is administered intravenously.
30. The method of claim 20 , wherein the complex is administered as an aerosol or liquid solution.
31. The method of claim 20 , and wherein the surface of the complex is positively charged.
32. The method of claim 20 , wherein the at least one protamine sulfate or chloride salt is from about 20 to about 100 amino acids in length.
33. The method of claim 20 , wherein the complex further comprises a neutral phospholipid species.
34. The method of claim 20 , wherein the ratio of the nucleic acid:lipid:polycation is, 1 μg/0.1 nmol/0.01 μg to about 1 μg/200 nmol/100 μg.
35. The complex of claim 1 , wherein the polycation is the histone.
36. The complex of claim 1 , wherein the polycation is the peptide comprising polylysine.
37. The complex of claim 1 , wherein the polycation is the peptide comprising a nuclear localization sequence of SV40 large T antigen.
38. The complex of claim 37 , wherein the polycation is a synthetic peptide comprising a nuclear localization sequence of SV40 large T antigen.
39. The complex of claim 1 , wherein the solution is a liposomal solution.
40. The complex of claim 39 , wherein the liposomal solution comprises a cationic lipid and a neutral lipid.
41. The complex of claim 1 , wherein the polycation further comprises a targeting factor.
42. The complex of claim 1 , wherein the lipid further comprises a targeting factor.
43. The complex of claim 42 , wherein the targeting factor is directed to a cell surface receptor.
44. The method of claim 11 , wherein the polycation is the histone.
45. The method of claim 11 , wherein the polycation is the peptide comprising polylysine.
46. The method of claim 11 , wherein the polycation is the peptide comprising a nuclear localization sequence of SV40 large T antigen.
47. The method of claim 46 , wherein the polycation is a synthetic peptide comprising a nuclear localization sequence of SV40 large T antigen.
48. The method of claim 11 , wherein the solution is a liposomal solution.
49. The method of claim 48 , wherein the liposomal solution comprises a cationic lipid and a neutral lipid.
50. The method of claim 11 , wherein the polycation further comprises a targeting factor.
51. The method of claim 11 , wherein the lipid further comprises a targeting factor.
52. The method of claim 51 , wherein the targeting factor is directed to a cell surface receptor.
53. The method of claim 20 , wherein the polycation is the histone.
54. The method of claim 20 , wherein the polycation is the peptide comprising polylysine.
55. The method of claim 20 , wherein the polycation is the peptide comprising a nuclear localization sequence of SV40 large T antigen.
56. The method of claim 55 , wherein the polycation is a synthetic peptide comprising a nuclear localization sequence of SV40 large T antigen.
57. The method of claim 20 , wherein the solution is a liposomal solution.
58. The method of claim 57 , wherein the liposomal solution comprises a cationic lipid and a neutral lipid.
59. The method of claim 20 , wherein the polycation further comprises a targeting factor.
60. The method of claim 20 , wherein the lipid further comprises a targeting factor.
61. The method of claim 60 , wherein the targeting factor is directed to a cell surface receptor.
62. The complex of claim 1 , wherein the nucleic acid, the lipid, and the polycation are present in a ratio such that the noncovalent complex has a positive charge excess of lipid and polycation to nucleic acid at pH 6.0-8.0.
63. The method of claim 11 , wherein the nucleic acid is added to the lipid and the polycation in a ratio such that the noncovalent complex has a positive charge excess of lipid and polycation to nucleic acid at pH 6.0-8.0.
64. The method of claim 20 , wherein the nucleic acid, the lipid, and the polycation are present in a ratio such that the noncovalent complex has a positive charge excess of lipid and polycation to nucleic acid at pH 6.0-8.0.
65. The complex of claim 1 , wherein the polycation is up to about 500 amino acids in length.
66. The complex of claim 65 , wherein the polycation is the peptide comprising polylysine.
67. The complex of claim 65 , wherein the polycation is about 20 to about 100 amino acids in length.
68. The complex of claim 66 , wherein the polycation is about 20 to about 35 amino acids in length.
69. The complex of claim 65 , wherein the polycation is about 25 to about 50 amino acids in length.
70. The complex of claim 1 , wherein the polycation has a molecular weight of from 300 to 200,000 Daltons.
71. The complex of claim 70 , wherein the polycation is the peptide comprising polylysine.
72. The method of claim 20 , wherein the polycation is up to about 500 amino acids in length.
73. The method of claim 72 , wherein the polycation is the peptide comprising polylysine.
74. The method of claim 72 , wherein the polycation is about 20 to about 100 amino acids in length.
75. The method of claim 73 , wherein the polycation is about 20 to about 35 amino acids in length.
76. The method of claim 72 , wherein the polycation is about 25 to about 50 amino acids in length.
77. The method of claim 20 , wherein the polycation has a molecular weight of from 300 to 200,000 Daltons.
78. The method of claim 77 , wherein the polycation is the peptide comprising polylysine.
79. The complex of claim 36 , wherein the polycation is about 25 to about 50 amino acids in length.
80. The method of claim 45 , wherein the polycation is about 25 to about 50 amino acids in length.
81. The method of claim 54 , wherein the polycation is about 25 to about 50 amino acids in length.